Welcome to our dedicated page for Lilly Eli & news (Ticker: LLY), a resource for investors and traders seeking the latest updates and insights on Lilly Eli & stock.
Eli Lilly & Co. develops and commercializes medicines across cardiometabolic disease, oncology, immunology, neuroscience and genetic medicine. Company news commonly covers product and pipeline developments for medicines such as Mounjaro, Zepbound, Foundayo, Omvoh, Verzenio, Jaypirca and Taltz, including clinical data, regulatory approvals and treatment-indication updates.
Lilly updates also include operating results, financial guidance, dividends, business development agreements and manufacturing expansion. Recent company communications highlight investment in active pharmaceutical ingredient capacity and genetic medicine production, alongside recurring disclosures about demand for diabetes, obesity, immune-disease and cancer therapies.
Eli Lilly (NYSE: LLY) announced Foundayo (orforglipron) is now available in the U.S. after FDA approval on April 1, 2026, with retail pharmacy shipping beginning April 9, 2026.
Foundayo is a once-daily oral GLP-1 for adults with obesity or overweight with weight-related problems, showing an average weight loss of 27.3 pounds (12.4%) at the highest dose in ATTAIN-1.
Eli Lilly (NYSE:LLY) announced FDA approval of Foundayo™ (orforglipron) for adults with obesity or overweight with weight-related conditions, available by prescription immediately and shipping from April 6, 2026. In ATTAIN-1, the highest dose produced an average 27.3 lb (12.4%) weight loss versus 2.2 lb (0.9%) placebo; overall trial participants lost 25 lb (11.1%) versus 5.3 lb (2.1%) placebo.
Foundayo will be distributed via LillyDirect with commercial copays from $25/month and self-pay starting at $149/month; Medicare Part D access may begin July 1, 2026. Safety warnings include potential thyroid tumors and common GI side effects.
Eli Lilly (NYSE: LLY) agreed to acquire Centessa Pharmaceuticals for $38.00 cash per share plus one CVR, yielding up to $47.00 per share if regulatory milestones are met. The upfront consideration implies an aggregate equity value of ~$6.3 billion and the CVR adds potential ~$1.5 billion.
The deal expands Lilly's neuroscience footprint into sleep medicine by adding Centessa's OX2R agonist portfolio, including lead candidate cleminorexton (Phase 2a) targeting narcolepsy and idiopathic hypersomnia. Closing is expected in Q3 2026, subject to shareholder, High Court and regulatory approvals.
Eli Lilly (NYSE: LLY) reported Phase 3b TOGETHER-PsA results showing that concomitant Taltz (ixekizumab) plus Zepbound (tirzepatide) was superior to Taltz alone at Week 36 across the primary endpoint and all key secondaries.
The combination delivered ACR50 plus ≥10% weight reduction in 31.7% versus 0.8%, higher ACR50 (33.5% vs 20.4%), greater ≥10% weight loss (84.5% vs 4.5%) and improved MDA, hsCRP, HAQ-DI, FACIT-Fatigue and SF-36 MCS.
Lilly (NYSE: LLY) reported interim ADlong Phase 3b data on March 27, 2026 showing long-term durability for EBGLYSS (lebrikizumab-lbkz) in moderate-to-severe atopic dermatitis. Observed results up to four years: EASI-75 94%, EASI-90 75%, IGA 0/1 68%, Pruritus NRS ≤4 78%.
Most patients (77%) received monotherapy, 80% achieved outcomes without topical corticosteroids, and monthly maintenance dosing produced sustained control; safety in year one was consistent with known profile.
Eli Lilly (NYSE: LLY) reported positive topline Phase 3 results for retatrutide in TRANSCEND-T2D-1 on March 19, 2026. At 40 weeks, retatrutide produced up to 2.0% A1C reduction and up to 16.8% weight loss (36.6 lbs) versus placebo, meeting primary and all key secondary endpoints.
Improvements were seen across doses (4 mg, 9 mg, 12 mg) and cardiovascular risk markers; common adverse events were nausea, diarrhea and vomiting, mostly during dose escalation.
Lilly (NYSE: LLY) reported positive topline Phase 3 ADorable-1 results for EBGLYSS (lebrikizumab-lbkz) in patients aged six months to 18 years with moderate-to-severe atopic dermatitis on March 16, 2026. At Week 16, EBGLYSS achieved EASI-75 63%, IGA 0,1 44%, EASI-90 39% and Pruritus NRS ≥4 improvement 35%. Safety was consistent with adult/adolescent studies, with no new signals and no injection site pain reported. Lilly plans regulatory submissions for potential pediatric label updates; the ADorable program and a 52-week extension continue.
Eli Lilly (NYSE: LLY) launched the Lilly Employer Connect platform on March 5, 2026 to expand employer-sponsored access to obesity medicines. The program starts with over 15 independent program administrators and offers Zepbound KwikPen at a discounted price of $449 per device across all doses to participating network pharmacies.
The platform enables flexible cost-share models and nationwide pharmacy support, while preserving provider and patient choice. Clinical data cited include SURMOUNT-1 (15 mg: 20.9% mean weight loss at 72 weeks vs 3.1% placebo) and SURMOUNT-5 open-label comparisons.
Eli Lilly (NYSE: LLY) announced a positive CHMP opinion recommending Olumiant (baricitinib) for adolescents ages 12 to <18 with severe alopecia areata. The recommendation is based on Phase 3 BRAVE-AA-PEDS results showing 42.4% achieved ≥80% scalp hair coverage at 36 weeks (4 mg).
The opinion moves to the European Commission for final action, expected in one to two months; a U.S. decision is expected in the second half of 2026.
Chondrosarcoma market (covering 7MM) is forecast to grow from 2026–2036 as diagnosis improves and new therapies advance. Approximately 1,400 incident US cases were reported in 2024–25. Emerging drugs include Ozekibart (INBRX-109), TIBSOVO (ivosidenib), and LY3410738 (LLY), with planned regulatory filings and ongoing pivotal trials.
The pipeline remains limited; however, Fast Track designations, positive Phase II topline data, a planned BLA in Q2 2026, and a Phase III primary completion expected Feb 2028 could reshape care for unresectable and metastatic disease.